Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
| 适应症 | Treatment Resistant Major Depressive Disorder |
|---|---|
| 分期 | 4期 |
| 申办方 | Massachusetts General Hospital |
| 状态 | 已完成 |
| 受试者人数 | 278 人 |
| 干预（药物） | Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR |
| 开始日期 | 2017年7月13日 |
| 完成日期 | 2022年4月24日 |
| 结果公布日 | 2026年7月9日 |
摘要
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.
Montgomery-Asberg Depression Rating Scale (MADRS)
| Aripiprazole Augmentation | -14.9 ± 1.1 points |
|---|---|
| rTMS Augmentation | -17.39 ± 1.3 points |
| Switch to Venlafaxine XR/Duloxetine | -13.22 ± 1.1 points |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital